Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
Bulios Fair Price
$5.94
27.5% upside
Current Price
$4.66
According to Bulios Fair Price, ORMP is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Oramed Pharmaceuticals Inc. is an Israeli biotechnology company specializing in the development of oral drugs for patients with diabetes. The company focuses on the research and development of oral insulin and other peptide-based drugs that aim to replace the need for injectable administration. Oramed Pharmaceuticals seeks to provide more convenient and effective treatment options for patients with diabetes. Shares of Oramed Pharmaceuticals Inc. are traded on the stock exchange and may be an interesting investment opportunity for those following innovations in diabetes treatment.
Sector
Healthcare
Industry
Biotechnology
CEO
Nadav Kidron
Employees
13
Headquarters
New York City
Upcoming events
Earnings
Upcoming earnings report